Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.58 |
| ▸ | P2RX2 | Q9UBL9 | 9/20 | 0.58 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276299 | 0.87 | P2RX3 (0.57) | P2RX3P2RX2HPGDS | |
| SCHEMBL2279542 | 0.84 | P2RX3 (0.56) | P2RX3P2RX2HPGDS | |
| SCHEMBL4319907 | 0.83 | P2RX3 (0.55) | P2RX3P2RX2HPGDS | |
| SCHEMBL2276142 | 0.82 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL4160065 | 0.82 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL2279648 | 0.82 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL4161780 | 0.82 | P2RX3 (0.63) | P2RX3P2RX2 | |
| SCHEMBL359328 | 0.81 | P2RX3 (0.55) | P2RX3P2RX2HPGDS | |
| SCHEMBL4329491 | 0.80 | P2RX3 (0.53) | P2RX3P2RX2HPGDS | |
| SCHEMBL4160076 | 0.79 | P2RX3 (0.63) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | claimed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2013-10-31 | — | — | US | disclosed |
| CN-101903348-B | Pyrazole-substituted arylamides | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | disclosed |
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2234976-B1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| CN-101903348-A | Novel pyrazole-substituted arylamides | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885HPGDS 1167/4885 |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885HPGDS 1167/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885HPGDS 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.